Orphagen Receives $446,635 NIH Phase I SBIR Grant To Treat Retina Pigmentosa (RP)

Orphagen Pharmaceutical was awarded a $446,635 NIH National Center for Advancing Translational Sciences (NCATS) Phase I SBIR grant to Investigate Novel Small Molecules to treat Retina Pigmentosa (RP). SDEE member Scott Thacher, Orphagen's founder and CEO, is a Principal Investigator of the grant. 

Each year thousands of Americans are diagnosed with RP, a complex neurodegenerative disease caused by mutations in more than 90 different genes. RP initially presents as loss of night vision, but progresses to loss of central vision and eventual blindness. There is no cure. Orphagen has identified small molecule compounds that could significantly delay degeneration in as many as 40% of RP patients.

Attend SDEE Events Donate | Sponsor SDEE Become a Member

Connect with SDEE

Sign Up for SDEE Newsletter


Morrison Foerster Alexandria


Takeda San Diego BDO logo


Barney and Barney Longfellow Pineapple.gif

SDEE is a nonprofit 501(c)(3) organization founded by local San Diego entrepreneurs
in order to provide a voice for the early stage start-up, to support new entrepreneurs and their companies,
and to sponsor networking and educational events
to help develop the skills necessary to bring funding, business, and jobs to the San Diego area.

© 2015 San Diego Entrepreneurs Exchange. All Rights Reserved